Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NWB7
UPID:
IFT57_HUMAN
Alternative names:
Dermal papilla-derived protein 8; Estrogen-related receptor beta-like protein 1; HIP1-interacting protein; MHS4R2
Alternative UPACC:
Q9NWB7; Q96DA9
Background:
Intraflagellar transport protein 57 homolog (IFT57) plays a pivotal role in cilia formation and sonic hedgehog signaling, essential for cellular communication and development. It interacts with HIP1 to induce apoptosis and may regulate transcription of caspase genes, highlighting its multifunctionality. Known by alternative names such as Dermal papilla-derived protein 8 and Estrogen-related receptor beta-like protein 1, IFT57's complexity is underscored by its DNA-binding capability.
Therapeutic significance:
IFT57's involvement in Orofaciodigital syndrome 18, characterized by distinct facial and digital malformations, underscores its therapeutic potential. Understanding IFT57's role could open doors to innovative treatments for this and possibly other ciliopathies, leveraging its fundamental biological functions.